Details for Patent: 9,572,867
✉ Email this page to a colleague
Title: | Treatment of short bowel syndrome patients with colon-in-continuity |
Abstract: | Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. |
Inventor(s): | Sanguinetti; Elizabeth L. (Salt Lake City, UT), Marriott; Thomas B. (Sandy, UT), Lopansri; Jennifer (Park City, UT), Blosch; Consuelo M. (Seattle, WA) |
Assignee: | Shire-NPS Pharmaceuticals, Inc. (Bedminster, NJ) |
Filing Date: | Oct 05, 2016 |
Application Number: | 15/286,001 |
Claims: | 1. A method of reducing recurrence of kidney stones in a patient having short bowel syndrome, who has previously suffered from at least one kidney stone, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a closing regimen effective to reduce the likelihood of kidney stone recurrence in said patient. 2. The method as defined in claim 1, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 5 to 500 .mu.g/kg. 3. The method as defined in claim 2, wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 .mu.g/kg. 4. The method as defined in claim 1, wherein the [Gly2]hGLP-2 is administered by subcutaneous injection. 5. The method as defined in claim 4, wherein the subcutaneous injection is into the abdomen, thigh, or arm. 6. The method as defined in claim 1, wherein the patient is an adult. 7. The method as defined in claim 1, wherein said regimen comprises administration of said [Gly2]hGLP-2 over a period of at least 21 days. 8. The method as defined in claim 1, wherein said patient is an adult and the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 .mu.g/kg by subcutaneous injection. |